Published • loading... • Updated
Ipsen to Acquire Memo Therapeutics AG, Adding First-in-Class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
The deal includes a 200 million euro upfront payment and could top 700 million euro if development and sales milestones are met.
- On Wednesday, Ipsen announced a definitive agreement to acquire Memo Therapeutics AG, focusing on potravitug, a first-in-class monoclonal antibody targeting BK polyomavirus in kidney transplant recipients.
- BK polyomavirus reactivation affects approximately 30% of kidney transplant patients within the first year, yet no approved targeted therapies exist, forcing clinicians to reduce immunosuppression and risking graft rejection.
- The Phase II SAFE KIDNEY II trial demonstrated potravitug's efficacy, with biopsy-proven BK polyomavirus associated nephropathy declining from 51.2% to 31.6% in the treatment group by week 20, versus no change in placebo.
- Shareholders of Memo Therapeutics AG will receive €200 million at closing, with deferred payments pushing total potential consideration above €700 million, expected during Q3 2026 subject to customary conditions.
- Ipsen plans to initiate the SAFE KIDNEY III trial later this year, while Memo Therapeutics AG transfers unrelated assets including the DROPZYLLA platform to a newly incorporated company, Memorises Bio.
Insights by Ground AI
15 Articles
15 Articles
Baker McKenzie Advises on Memo Therapeutics' Sale to Ipsen and Related Carve-Out
Baker McKenzie advised Memo Therapeutics AG (“Memo Therapeutics”), a Swiss late-stage biotech company and its shareholders... The post Baker McKenzie Advises on Memo Therapeutics’ Sale to Ipsen and Related Carve-Out appeared first on Legal Desire Media and Insights.
Coverage Details
Total News Sources15
Leaning Left3Leaning Right2Center5Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 30%
C 50%
R 20%
Factuality
To view factuality data please Upgrade to Premium
